Pre-Meeting Categorical Seminars

Additional registration fees may apply. *Members who are also members of a Council or Center will receive a $20 discount when registering online for a Physician/Scientist Categorical. Not available for remote attendees.
SNMMI's Annual Meeting in-person attendance option allows you to add a pre-meeting categorical seminar to your registration. These full day sessions are designed to provide you with a deeper level of understanding as you examine a single topic of clinical, scientific, or academic interest.

Categorical #1: A New Decade Molecular Hybrid Imaging in Orthopedics and Rheumatology: Focus on bone and infection/inflammation
This categorical seminar consists of four thematically linked mini sessions on technical advances, as well as key clinical applications of PET/CT and SPECT/CT in orthopedics, infectious disease, and rheumatology. In the first part, the recent progress in radiopharmaceutical development for musculoskeletal imaging applications and advances in engineering and physics in SPECT/CT will be presented. Next, the clinical use of bone SPECT/CT in orthopedics is illustrated with a focus on the role of biomechanics in upper and lower limb joint related conditions, followed by applications of bone PET/CT in orthopedics and related specialties. The final mini session will cover bone and prosthesis related infections, emphasizing the clinical indications, imaging algorithms, and impact in patient management. The session will conclude with a review of the FDG-PET/CT role in polymyalgia rheumatica and rheumatoid arthritis, and NaF-PET/CT in rare bone disease (fibrous dysplasia, Paget’s disease, bone viability). 

Categorical #2: Imaging Biomarkers in Neurodegenerative and Neuropsychiatric Disorders - Current Clinical Use and Future Directions
This Categorical seminar has been designed to provide a better understanding of the current clinical use of imaging biomarkers in the diagnosis of most challenging neurodegenerative conditions. Interestingly, it includes a critical view about the procedures to measure and quantify PET images, as well as a review of the advantages and disadvantages of alternative biomarkers. In addition, this categorical covers the future directions in the development of radioligands for neuropathological targets involved in neurodegenerative and neuropsychiatric disorders. The content is focused on improving the understanding of the clinical uses of neuroimaging biomarkers, as well as gaining a perspective on the more recent developments in the field.

Categorical #3: Radiopharmaceutical Therapies - Current and Upcoming Theranostic Agents
This categorical seminar will address current and upcoming RPT modalities. Theranostics is rapidly growing, and new agents have been developed that have been recently approved for clinical use, while others are currently in clinical trials. The VISION trial and potential need for translation of PSMA RLT to clinics in US, this session will address clinical results and technical aspects needed to prepare NM community for PSMA RLT. The session will also provide overview and updates on use of PRRT, RLT, and MIBG therapies, as well as new agents in radiopharmaceutical therapy (RPT). Reimbursement and technical aspects of RPT will also be discussed. The session will also include case examples and nuts and bolts on the various RPTs. An overview of clinical data-studies will be presented. Novel agents and the applications such as FAPI or trials with combination treatments will be discussed.

Categorical #4: Image Guided Decision Making and Therapy for Optimal Cardiovascular Patient Care
This categorical seminar is a six-part, clinically oriented session covering important topics relevant to cardiovascular nuclear imaging. These topics will include a comprehensive discussion of forthcoming hybrid nuclear/CT imaging guidelines, clinical uses of cardiac PET myocardial blood flow quantifications, controversies in the new ACC/AHA chest pain guidelines, an update on infiltrative cardiomyopathies, novel imaging ‘outside the myocardium’ such as in PVD, and perspectives on nuclear cardiology practice from international centers. Cases examples and clinical vignettes will be part of each session and audience participation will be encouraged.

Categorical #5: Molecular Imaging of Immunotherapy Response
This categorical seminar provides: an overview of the immunotherapy agents in clinical development, a foundation for our understanding of immunotherapy effects with conventional imaging such as FDG PET, CT, and MRI. In addition, a summary of the molecular imaging approaches being developed to monitor autoimmune responses, including T-cell targeted and macrophage/ monocyte imaging approaches, and challenges in the development of these approaches will be explored. The seminar will focus on how these novel approaches could enable the imaging community to contribute to the improvement of patient treatment outcomes with immune checkpoint inhibitors. This is a timely session given the ever-increasing number of immunotherapy agents being developed and growing clinical need for assessing treatment efficacy and response.

Categorical #6: What's Now and What's Next for Prostate Cancer?
Advances in the diagnosis and treatment of prostate cancer have dominated nuclear medicine news. The approvals of Ga-68 and F-18-labelled PSMA imaging agents and Lu177-PSMA therapy have changed the management of patients with prostate cancer. These advances are just the beginning and nuclear medicine practitioners need to know the entire prostate cancer landscape. This categorical seminar will review other treatments under development for prostate cancer and provide a review of the two large phase 3 randomized VISION and TheraP trials. The future roles of PSMA therapy including the use of alpha-emitters, will be discussed. Finally other promising agents in prostate cancer management including non-radiopharmaceutical PSMA and other targeted radiotracers such as RM-2 will be reviewed. Finally, another hot topic—the role of dosimetry in PSMA radioligand therapy will be debated. This is a must-attend session for anyone imaging or treating patients with prostate cancer. 

Categorical #7: Image Quantification and Dosimetry in Radiopharmaceutical Therapy
This categorical seminar will review best practices for determination of absorbed dose based on planar as well as 3D images acquired during or in preparation for radiopharmaceutical therapies. This session will consist of two parts: 1) Activity quantification in nuclear medicine images, focusing on gamma-emitting isotopes, and 2) Computational methods for estimating absorbed dose. In part one we will review the best practices associated with estimating activity from planar, SPECT and SPECT/CT nuclear medicine images. This will include a discussion on quantitative reconstruction methods for SPECT/CT. For non-quantitative planar or SPECT images we will review the use of phantom acquisitions to derive empirical calibration coefficients. Part two will build on the image quantification topic above and include a review of best practices in absorbed dose estimation.

Categorical #8: The Design, Development and Translation of Novel Radiotherapeutics
This categorical seminar will cover a wide spectrum of current and new radiotherapeutics/theranostics and will cover basic isotope production, molecular target selection, radiopharmaceutical design and development, to dosimetry, regulatory filing and human translation. Special attention will be given to the radiotherapeutics targeting oncology indications, but other disease application will be also discussed. Lessens and differences between imaging biomarkers (diagnostic) and radiotherapeutic agents (treatment) in preclinical and clinical setting will be elaborated upon. The session is comprehensive and designed for a broad audience and is suitable for physicians, scientists, technologists, pharmacists, and laboratory professionals who are interested to learn about the unprecedented potential of novel radiotherapeutics in providing insights into basic and translational research and paradigm shifting clinical solutions.